Aortic Valve Replacement Market Size, Share and Growth 2026-2034

Market Overview:

The Aortic Valve Replacement Market is experiencing significant expansion, driven by Rising Incidence of Calcific Aortic Stenosis and Valvular Defects, Expanding Approval for Low-Risk Patient Populations, and Favorable Reimbursement Frameworks in Developing Economies. According to IMARC Group's latest research publication, "Aortic Valve Replacement Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2026-2034", The global aortic valve replacement market size reached USD 12.3 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 27.1 Billion by 2034, exhibiting a growth rate (CAGR) of 8.87% during 2026-2034.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

Download a sample PDF of this report: https://www.imarcgroup.com/aortic-valve-replacement-market/requestsample

Our Report Includes:

• Market Dynamics
• Market Trends and Outlook
• Competitive Analysis
• Industry Segmentation
• Strategic Recommendations

Growth Factors in the Aortic Valve Replacement Industry:

• Rising Incidence of Calcific Aortic Stenosis and Valvular Defects

The prevalence of heart valve disease is increasing worldwide and is mainly related to the aging population․ Calcific aortic stenosis (narrowing of the aortic valve) is now the leading reason for cardiovascular intervention in the older population․ As life expectancy increases, the number of patients requiring advanced valve replacement therapy is also increasing․ However, the rising prevalence of lifestyle-related comorbidities such as obesity, hypertension, and diabetes has caused accelerated rate of valvular degeneration․ Thus, more and more patients are being screened by the physicians to increase diagnosis, resulting in the continued influx of patients eligible for surgical and transcatheter interventions․

• Expanding Approval for Low-Risk Patient Populations

Transcatheter aortic valve replacement (TAVR) has been a primary growth driver thus far․ TAVR has so far been approved for high-risk and inoperable patients with aortic stenosis․ Approval is being expanded to include intermediate and low-risk patients as the clinical trials for TAVR in this space continue to establish the safety and efficacy of the procedure․ Younger and healthier patients are part of the addressable patient population as they are more likely to seek out transcatheter procedures for their lower invasiveness and shorter recovery times․ As delivery systems and valve durability continue to advance, transcatheter valve interventions will likely also become viable therapies for patients previously deemed acceptable candidates for customary open heart surgery․

• Favorable Reimbursement Frameworks in Developing Economies

With government and private insurance programs, aortic valve therapy is becoming more widely available in developing markets․ For instance, heart valve procedures are beginning to be incorporated into normal procedures in national health programs in the Asia-Pacific and Latin American regions․ Aggressive pricing and subsidized cardiac care programs in China and India may reduce the cost barrier to access advanced treatment in these markets․ Improved reimbursement policies may drive acceptance of aortic valve replacement by patients, and investment in dedicated cardiac catheterization laboratories and hybrid operating rooms supporting aortic valve procedures by hospitals․

Key Trends in the Aortic Valve Replacement Market

• Transition Toward Next-Generation Biomimetic and Sutureless Valves

The focus of current research is to develop sutureless and tissue engineered valves that mimic the movement/physiology of natural valves․ Sutureless valves are widely implemented in the surgical setting and have been shown to reduce cross-clamp and Cpb time, and improve outcomes for patients undergoing replacement of their cardiac valves․ An equally promising approach that is developing in parallel, especially among researchers, is the design and manufacture of bioengineered valves that, through biocompatible scaffolds, would address and reduce the risk of calcification and immune response while addressing durability limitations in conventional bioprosthetic valves that would otherwise require repeat procedures․

• Integration of Virtual Reality (VR) and 3D Planning in Pre-Operative Care

Advanced visualization technologies are now common for the planning of complex valve replacements, with 3D-printed heart models and virtual reality simulations allowing surgeons and cardiologists to explore the patient's unique anatomy prior to the procedure, helping with accurate valve sizing and pre-emptive identification of complications such as coronary artery occlusion, thus limiting risks and ensuring optimal valve size and positioning in the native valve annulus to the anatomy of the patient's heart and maximizing long-term hemodynamic performance․

• Growing Dominance of Ambulatory Surgical Centers (ASCs)

There is a trend for heart valve repair/replacement to migrate from a hospital setting to an ambulatory surgical center․ The minimally intrusive nature of TAVR and other catheter-based valve therapies makes this a reasonable option․ In addition, ASCs are a less expensive and less complex environment for care․ Because ASCs can provide patients with protocols that allow faster recovery and shorter stays than hospital wards, many patients can be discharged sooner than in a hospital ward․ As technology makes valve replacement and repair procedures less intrusive, ASCs may be incorporated into a larger portion of the healthcare system, further expanding access to specialized cardiac treatment and reducing expenses․

We explore the factors driving the growth of the market, including technological advancements, consumer behaviors, and regulatory changes, along with emerging aortic valve replacement market trends.

Leading Companies Operating in the Global Aortic Valve Replacement Industry:

• Abbott Laboratories
• Anteris Technologies Ltd.
• Boston Scientific Corporation
• Coroneo Inc.
• CryoLife Inc.
• Edwards Lifesciences Corporation
• JenaValve Technology Inc.
• LifeNet Health Inc.
• LivaNova PLC
• Medtronic plc
• Thubrikar Aortic Valve Inc.

Aortic Valve Replacement Market Report Segmentation:

Breakup by Surgery:

• Open Surgery
• Minimally Invasive Surgery

Minimally invasive surgery represented the largest segment due to patient preference for procedures with fewer complications and shorter recovery times.

Breakup by Product:

• Transcatheter Aortic Valve
• Sutureless Valve
• Others

Transcatheter aortic valve accounted for the largest market share due to its innovative catheter-based delivery system eliminating need for open-heart surgery.

Breakup by End Use:

• Hospitals
• Ambulatory Surgery Centers
• Others

Hospitals represented the largest segment due to comprehensive cardiac care capabilities and specialized equipment required for complex procedures.

Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America was the largest market for aortic valve replacement due to extensive research and development activities, well-established healthcare facilities, and integration of advanced technologies.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1–201971–6302